PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend

Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says The committee met urgently in July in response to AstraZeneca’s announcement it would remove Zoladex from the market, risking leaving more than 7,500 women with breast cancer without an alternative treatment.